Pathological Ventricular Remodeling: Mechanisms Part 1 of 2
暂无分享,去创建一个
[1] G. Filippatos,et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. , 2008, Journal of the American College of Cardiology.
[2] Yasushi Matsumura,et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress , 2007, Nature Medicine.
[3] M. Miragoli,et al. Myofibroblasts Induce Ectopic Activity in Cardiac Tissue , 2007, Circulation research.
[4] J. Funder. Reconsidering the Roles of the Mineralocorticoid Receptor , 2009, Hypertension.
[5] P. Mulder,et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. , 2008, European heart journal.
[6] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[7] A. Jánosi,et al. Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.
[8] W. Koch,et al. Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade , 2012, Gene Therapy.
[9] Arantxa González,et al. Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients , 2001, Circulation.
[10] A. Varki,et al. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. , 2009, Blood.
[11] Joseph A. Hill,et al. Pathological Ventricular Remodeling: Therapies Part 2 of 2 , 2013, Circulation.
[12] E. Olson,et al. Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.
[13] C. Long,et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.
[14] Joseph A. Hill,et al. Electrophysiological remodeling in heart failure. , 2010, Journal of molecular and cellular cardiology.
[15] D. Sane,et al. Statin Therapy May Be Associated With Lower Mortality in Patients With Diastolic Heart Failure: A Preliminary Report , 2005, Circulation.
[16] Nan Jiang,et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. , 2012, The Journal of clinical investigation.
[17] Karl-Ludwig Laugwitz,et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages , 2005, Nature.
[18] E. Neilson,et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.
[19] M. Al-mallah,et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. , 2007, Archives of internal medicine.
[20] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[21] D. Sica,et al. Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches , 2011, European heart journal.
[22] M. Drazner,et al. Does load-induced ventricular hypertrophy progress to systolic heart failure? , 2005, American journal of physiology. Heart and circulatory physiology.
[23] Y. Taenaka,et al. Influence of prolonged ventricular assistance on myocardial histopathology in intact heart. , 1996, The Annals of thoracic surgery.
[24] Scott T Acton,et al. Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy. , 2012, Journal of molecular and cellular cardiology.
[25] S. Russell,et al. The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. , 2010, European heart journal.
[26] D. Levy,et al. Sex differences in cardiac adaptation to isolated systolic hypertension. , 1993, The American journal of cardiology.
[27] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[28] J. Richardson,et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. , 2007, The Journal of clinical investigation.
[29] D. Torella,et al. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration , 2006, Nature Clinical Practice Cardiovascular Medicine.
[30] Chad E. Grueter,et al. A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13 , 2012, Cell.
[31] V. Regitz-Zagrosek,et al. Regression of Myocardial Hypertrophy After Aortic Valve Replacement: Faster in Women? , 2009, Circulation.
[32] A. Maseri,et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2). , 1993, The New England journal of medicine.
[33] M. Kinoshita,et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. , 2001, Journal of the American College of Cardiology.
[34] K. Youker,et al. Therapeutic plasma exchange a potential strategy for patients with advanced heart failure , 2010, Journal of clinical apheresis.
[35] Antti Tanskanen,et al. Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling. , 2008, Physiological genomics.
[36] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[37] R. Gomer,et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice , 2006, Proceedings of the National Academy of Sciences.
[38] D. May,et al. Vascular Endothelial Growth Factor–Induced Neovascularization Rescues Cardiac Function But Not Adverse Remodeling at Advanced Ischemic Heart Disease , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[39] Stefanie Dimmeler,et al. Impaired CXCR4 Signaling Contributes to the Reduced Neovascularization Capacity of Endothelial Progenitor Cells From Patients With Coronary Artery Disease , 2005, Circulation research.
[40] C. Long,et al. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. , 1998, Cardiovascular research.
[41] A. Louis,et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 , 2001, European journal of heart failure.
[42] D. Cox,et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.
[43] G. Booz,et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. , 1993, Circulation research.
[44] Y. Tsujimoto,et al. Another way to die: autophagic programmed cell death , 2005, Cell Death and Differentiation.
[45] R. Henkelman,et al. Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. , 2011, Cardiovascular research.
[46] Henry Krum,et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.
[47] F. Bushman,et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.
[48] Akshay S. Desai,et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. , 2011, European heart journal.
[49] Y. Dor,et al. Induction of Vascular Networks in Adult Organs: Implications to Proangiogenic Therapy , 2003, Annals of the New York Academy of Sciences.
[50] Brian O'Rourke,et al. Electrophysiological Consequences of Dyssynchronous Heart Failure and Its Restoration by Resynchronization Therapy , 2009, Circulation.
[51] Richard T. Lee,et al. Regeneration of the heart , 2011, EMBO molecular medicine.
[52] W. Thomas,et al. Non-genomic actions of aldosterone: From receptors and signals to membrane targets , 2012, Molecular and Cellular Endocrinology.
[53] C. Tschöpe,et al. Renin Inhibition Improves Cardiac Function and Remodeling After Myocardial Infarction Independent of Blood Pressure , 2008, Hypertension.
[54] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[55] F. Sweep,et al. Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training , 2006, Aging cell.
[56] A. Carayon,et al. , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of , 1999 .
[57] A. Maseri,et al. Age-Related Increase in Mortality among Patients with First Myocardial Infarctions Treated with Thrombolysis , 1993 .
[58] D. Klionsky,et al. Eaten alive: a history of macroautophagy , 2010, Nature Cell Biology.
[59] D. Mann,et al. Communication in the Heart: the Role of the Innate Immune System in Coordinating Cellular Responses to Ischemic Injury , 2012, Journal of Cardiovascular Translational Research.
[60] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[61] Lubo Zhang,et al. Hypoxia and fetal heart development. , 2010, Current molecular medicine.
[62] R. Shannon,et al. Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38&agr; MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy , 2010, Circulation. Heart failure.
[63] E. Frohlich,et al. The aging hypertensive heart: a brief update , 2008, Nature Clinical Practice Cardiovascular Medicine.
[64] F. Cacciapaglia,et al. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. , 2011, Autoimmunity reviews.
[65] M. Gheorghiade,et al. Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) , 2011, European journal of heart failure.
[66] D. Mann,et al. Inflammatory mediators and the failing heart: a translational approach. , 2003, Current molecular medicine.
[67] S. Werns. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .
[68] O. Kuss,et al. Age-dependent depression in circulating endothelial progenitor cells inpatients undergoing coronary artery bypass grafting , 2003 .
[69] M. Hopman,et al. Preserved cardiac function after chronic spinal cord injury. , 2006, Archives of physical medicine and rehabilitation.
[70] B. Jugdutt,et al. Vascular remodeling during healing after myocardial infarction in the dog model: effects of reperfusion, amlodipine and enalapril. , 2002, Journal of the American College of Cardiology.
[71] Shunichi Homma,et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. , 2011, Journal of the American College of Cardiology.
[72] David L Hayes,et al. Sustained Reverse Left Ventricular Structural Remodeling With Cardiac Resynchronization at One Year Is a Function of Etiology: Quantitative Doppler Echocardiographic Evidence From the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) , 2006, Circulation.
[73] F. Crea,et al. Sex-related differences in myocardial remodeling. , 2010, Journal of the American College of Cardiology.
[74] D. Klionsky,et al. Autophagy in the Eukaryotic Cell , 2002, Eukaryotic Cell.
[75] S. Silver,et al. Heart Failure , 1937, The New England journal of medicine.
[76] W. Stevenson,et al. Characterization of the Peri-Infarct Zone by Contrast-Enhanced Cardiac Magnetic Resonance Imaging Is a Powerful Predictor of Post–Myocardial Infarction Mortality , 2006, Circulation.
[77] G. Dorn,et al. Mechanical Unloading Activates FoxO3 to Trigger Bnip3‐Dependent Cardiomyocyte Atrophy , 2013, Journal of the American Heart Association.
[78] R. Kerber,et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. , 2000, Circulation.
[79] M. Simons,et al. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.
[80] Catherine A. Risebro,et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization , 2007, Nature.
[81] Jeroen J. Bax,et al. Results of the Predictors of Response to CRT (PROSPECT) Trial , 2008, Circulation.
[82] Xiaoxia Qi,et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors , 2012, Nature.
[83] Mark J Post,et al. Therapeutic angiogenesis in the heart: protect and serve. , 2007, Current opinion in pharmacology.
[84] M. Packer,et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.
[85] Nicolas Servant,et al. Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension. , 2007, Canadian journal of physiology and pharmacology.
[86] Wolfgang A Linke,et al. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. , 2007, Cardiovascular research.
[87] P. Anversa,et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. , 1997, Journal of molecular and cellular cardiology.
[88] M. Movsesian,et al. Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. , 1994, Circulation.
[89] D. Levy,et al. A Systematic Assessment of Causes of Death After Heart Failure Onset in the Community: Impact of Age at Death, Time Period, and Left Ventricular Systolic Dysfunction , 2011, Circulation. Heart failure.
[90] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[91] H. Willard,et al. X-inactivation profile reveals extensive variability in X-linked gene expression in females , 2005, Nature.
[92] Samuel Bernard,et al. Evidence for Cardiomyocyte Renewal in Humans , 2008, Science.
[93] P. Vandenabeele,et al. Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.
[94] Douglas L Mann,et al. Targeted anticytokine therapy and the failing heart. , 2005, The American journal of cardiology.
[95] James B. Young,et al. Clinical trials to "real-world" heart failure: applying risk stratification to deliver personalized care. , 2011, Heart failure clinics.
[96] I. Poornima,et al. Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat , 2008, Circulation. Heart failure.
[97] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[98] S. Prabhu. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. , 2004, Circulation research.
[99] E. Olson,et al. Cardiogenic small molecules that enhance myocardial repair by stem cells , 2008, Proceedings of the National Academy of Sciences.
[100] D. Torella,et al. Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration , 2003, Cell.
[101] Joseph A. Hill,et al. Diabetic cardiomyopathy and metabolic remodeling of the heart. , 2013, Life sciences.
[102] P. Buttrick,et al. Reverse Remodeling With Left Ventricular Assist Devices: A Review of Clinical, Cellular, and Molecular Effects , 2011, Circulation. Heart failure.
[103] D. Kass,et al. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.
[104] Masashi Komeda,et al. Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[105] C. H. Chen,et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. , 1999, Journal of the American College of Cardiology.
[106] Xueli Yuan,et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.
[107] C Michael Stein,et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.
[108] W Grossman,et al. Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.
[109] J. Ge,et al. Rationale and design of the β‐blocker in heart failure with normal left ventricular ejection fraction (β‐PRESERVE) study , 2010, European journal of heart failure.
[110] P. Kistler,et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. , 2011, Journal of the American College of Cardiology.
[111] H. Sostman,et al. Intact systolic left ventricular function in clinical congestive heart failure. , 1985, The American journal of cardiology.
[112] Anindita Das,et al. Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice , 2012, PloS one.
[113] S. Houser,et al. Abnormalities of calcium cycling in the hypertrophied and failing heart. , 2000, Journal of molecular and cellular cardiology.
[114] B. Pitt,et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. , 2008, Journal of the American College of Cardiology.
[115] C. Lavie,et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. , 2002, The American journal of cardiology.
[116] S. Majumdar,et al. Drug treatments for obesity: orlistat, sibutramine, and rimonabant , 2007, The Lancet.
[117] T. Prolla,et al. Age‐dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria , 2010, Aging cell.
[118] R. Kloner,et al. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. , 2012, Journal of the American College of Cardiology.
[119] J. Cleland,et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.
[120] M. Keane,et al. Reverse remodelling in heart failure with cardiac resynchronisation therapy , 2005, Heart.
[121] D. Rosenbaum,et al. Transmural Electrophysiological Heterogeneities Underlying Arrhythmogenesis in Heart Failure , 2003, Circulation research.
[122] H. Ushikoshi,et al. Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. , 2006, The American journal of pathology.
[123] L. Mestroni,et al. Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.
[124] O. Nielsen,et al. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N‐terminal pro brain natriuretic peptide: a 10‐year analysis from the Copenhagen Hospital Heart Failure Study , 2012, European journal of heart failure.
[125] M. Weis,et al. Cardiac allograft vasculopathy: recent developments. , 2008, Circulation.
[126] C. Hayward,et al. Gender-related differences in the central arterial pressure waveform. , 1997, Journal of the American College of Cardiology.
[127] Stephan Rohr,et al. Electrotonic Modulation of Cardiac Impulse Conduction by Myofibroblasts , 2006, Circulation research.
[128] G. Lamas,et al. Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients With Recent Myocardial Infarction: A Report From the Randomized Occluded Artery Trial , 2010, Circulation.
[129] E. Marbán,et al. Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens , 2007, Circulation.
[130] Jose H. Flores-Arredondo,et al. Immune Modulation in Heart Failure: Past Challenges and Future Hopes , 2011, Current Heart Failure Reports.
[131] Marcus F Stoddard,et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.
[132] Barry Greenberg,et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.
[133] Fatih Kocabaş,et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest , 2013, Nature.
[134] B. Blaxall,et al. Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits. , 2011, Journal of molecular and cellular cardiology.
[135] Li Qian,et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes , 2011, Nature.
[136] N. Farman,et al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.
[137] L. Goldberg. Heart Failure , 2010, Annals of Internal Medicine.
[138] M. Packer. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .
[139] Andrew R Coggan,et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. , 2004, The New England journal of medicine.
[140] Dudley J Pennell,et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.
[141] G. Novo,et al. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. , 2008, British journal of clinical pharmacology.
[142] Michael D. Schneider,et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[143] R. Arena,et al. PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.
[144] J. Ménard,et al. Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism , 2010, Hypertension.
[145] B. Howard,et al. Vascular Biomarkers in the Prediction of Clinical Cardiovascular Disease: The Strong Heart Study , 2012, Hypertension.
[146] M. Cohen,et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. , 1997, The American journal of cardiology.
[147] G. Sanz,et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.
[148] K. Swedberg,et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.
[149] Joseph A. Hill,et al. Electrical remodeling in cardiac hypertrophy. , 2003, Trends in cardiovascular medicine.
[150] S. Goldstein,et al. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. , 2000, Journal of the American College of Cardiology.
[151] W. Koch,et al. Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.
[152] Joseph A. Hill,et al. Calcineurin-dependent ion channel regulation in heart. , 2014, Trends in cardiovascular medicine.
[153] A. Khera,et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.
[154] J. Tamargo,et al. Novel therapeutic targets for the treatment of heart failure , 2011, Nature Reviews Drug Discovery.
[155] T. Asano,et al. Distinct Roles of Autophagy in the Heart During Ischemia and Reperfusion: Roles of AMP-Activated Protein Kinase and Beclin 1 in Mediating Autophagy , 2007, Circulation research.
[156] R. Burt,et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. , 2008, JAMA.
[157] E. McNally,et al. Genetic mutations and mechanisms in dilated cardiomyopathy. , 2013, The Journal of clinical investigation.
[158] Deepak M. Gupta,et al. A nonviral minicircle vector for deriving human iPS cells , 2010, Nature Methods.
[159] M. Berlan,et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.
[160] Francis G Spinale,et al. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.
[161] KenjiHayakawa,et al. Inhibition of Granulation Tissue Cell Apoptosis During the Subacute Stage of Myocardial Infarction Improves Cardiac Remodeling and Dysfunction at the Chronic Stage , 2003 .
[162] R. Shannon,et al. Glucagon‐like Peptide‐1 and Myocardial Protection: More than Glycemic Control , 2009, Clinical cardiology.
[163] P. Galuppo,et al. Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction , 2008, Circulation.
[164] Richard T. Lee,et al. Mammalian Heart Renewal by Preexisting Cardiomyocytes , 2012, Nature.
[165] P. Anversa,et al. Angiotensin II Induces Apoptosis of Adult Ventricular MyocytesIn Vitro , 1997 .
[166] D. Yellon,et al. Leptin, the obesity‐associated hormone, exhibits direct cardioprotective effects , 2006, British journal of pharmacology.
[167] G. Biondi-Zoccai,et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. , 2007, Journal of the American College of Cardiology.
[168] I. Komuro,et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.
[169] E. Marbán,et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. , 2012, Journal of the American College of Cardiology.
[170] S. Felix,et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. , 2006, American heart journal.
[171] C. G. Blomqvist,et al. Cardiac atrophy after bed rest and spaceflight. , 2001, Journal of applied physiology.
[172] D. Sica. Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.
[173] R. McKelvie,et al. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction , 2011, Circulation.
[174] Louis Hue,et al. The Randle cycle revisited: a new head for an old hat. , 2009, American journal of physiology. Endocrinology and metabolism.
[175] M. Burch,et al. Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.
[176] P. Elliott,et al. Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives , 2006, Circulation.
[177] Katherine C. Wu,et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.
[178] Caleb E. Finch,et al. Evolution of the human lifespan and diseases of aging: Roles of infection, inflammation, and nutrition , 2009, Proceedings of the National Academy of Sciences.
[179] T. Ichisaka,et al. Generation of germline-competent induced pluripotent stem cells , 2007, Nature.
[180] Daniel Berman,et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial , 2012, The Lancet.
[181] P. D. del Nido,et al. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. , 2004, The Annals of thoracic surgery.
[182] P. Poole‐Wilson,et al. The cardiac component of cardiac cachexia. , 2002, American heart journal.
[183] A. Cohen-Solal,et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.
[184] S. Solomon,et al. Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.
[185] Gregg S. Pressman,et al. Impact of obesity on total and cardiovascular mortality—fat or fiction? , 2011, Nature Reviews Cardiology.
[186] M. Packer. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. , 2011, Circulation. Heart failure.
[187] M. Maurer,et al. Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma , 2011, Current cardiovascular risk reports.
[188] J. Elmquist,et al. Adipose Tissue Biology and Cardiomyopathy: Translational Implications , 2012, Circulation research.
[189] Amir Lerman,et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.
[190] G. Sweeney,et al. Cardiac remodeling in obesity. , 2008, Physiological reviews.
[191] G. Taffet,et al. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. , 2008, Journal of the American College of Cardiology.
[192] R. Stewart,et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.
[193] B. Rothermel,et al. Autophagy in load-induced heart disease. , 2008, Circulation research.
[194] K. Pandey. Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. , 2011, Canadian journal of physiology and pharmacology.
[195] J. Loscalzo,et al. Cardiomyogenesis in the Aging and Failing Human Heart , 2012, Circulation.
[196] Zeneng Wang,et al. Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .
[197] H. N. Sabbah,et al. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current , 1999, Cellular and Molecular Life Sciences CMLS.
[198] Ajit Varki,et al. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. , 2008, Cancer research.
[199] Wojciech Zareba,et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.
[200] Hugh Calkins,et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.
[201] P. Sugden. An overview of endothelin signaling in the cardiac myocyte. , 2003, Journal of molecular and cellular cardiology.
[202] N. Wong,et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. , 2009, JACC. Cardiovascular imaging.
[203] Brandon K. Fornwalt,et al. Agreement Is Poor Among Current Criteria Used to Define Response to Cardiac Resynchronization Therapy , 2010, Circulation.
[204] Chang Yao,et al. Modification of Collagen Matrices for Enhancing Angiogenesis , 2005, Cells Tissues Organs.
[205] Joseph A. Hill,et al. Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with Cardiomyopathy , 2011, Pacing and clinical electrophysiology : PACE.
[206] E. Olson,et al. Reversibility of Adverse, Calcineurin-Dependent Cardiac Remodeling , 2011, Circulation research.
[207] S. Frøland,et al. Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment , 2001, Circulation.
[208] I. Benjamin,et al. Autophagy is an adaptive response in desmin-related cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.
[209] P. Galuppo,et al. Novel therapeutic approaches to post-infarction remodelling. , 2012, Cardiovascular research.
[210] M. Beer,et al. Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis , 2009, Circulation.
[211] D. Kass,et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. , 2007, Journal of the American College of Cardiology.
[212] D. Mikhailidis,et al. Should a statin be prescribed to every patient with heart failure? , 2008, Heart Failure Reviews.
[213] W. Paulus,et al. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. , 2011, European heart journal.
[214] W. Pu,et al. Epicardial epithelial-to-mesenchymal transition in injured heart , 2011, Journal of cellular and molecular medicine.
[215] D. Berry,et al. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. , 2012, American heart journal.
[216] Marc A Pfeffer,et al. Controversies in ventricular remodelling , 2006, The Lancet.
[217] Guido Kroemer,et al. The end of autophagic cell death? , 2012, Autophagy.
[218] E. Olson,et al. Transient Regenerative Potential of the Neonatal Mouse Heart , 2011, Science.
[219] R. Holubkov,et al. Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy , 2001, Circulation.
[220] G. Baumann,et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[221] E. Olson,et al. Cardiac plasticity. , 2008, The New England journal of medicine.
[222] S. Nitter‐Hauge,et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.
[223] B. Liu,et al. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. , 2013, American journal of physiology. Heart and circulatory physiology.
[224] M C Oz,et al. Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.
[225] R. W. Joyner,et al. Remodeling of Early-Phase Repolarization: A Mechanism of Abnormal Impulse Conduction in Heart Failure , 2006, Circulation.
[226] J. Fildes,et al. The immune system and chronic heart failure: is the heart in control? , 2009, Journal of the American College of Cardiology.
[227] V. Roger,et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. , 2009, Journal of the American College of Cardiology.
[228] H. Krumholz,et al. The obesity paradox: body mass index and outcomes in patients with heart failure. , 2005, Archives of internal medicine.
[229] D. Levy,et al. Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.
[230] E. D. du Toit,et al. Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats , 2012, Disease Models & Mechanisms.
[231] R. Bassel-Duby,et al. Diminished Cardiac Fibrosis in Heart Failure is Associated with Altered Ventricular Arrhythmia Phenotype , 2010, Journal of cardiovascular electrophysiology.
[232] C. Heeschen,et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. , 2007, Journal of the American College of Cardiology.
[233] P. Vardas,et al. Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study , 2012, European journal of heart failure.
[234] I. Shiojima,et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.
[235] J. Fang,et al. Rise of the machines--left ventricular assist devices as permanent therapy for advanced heart failure. , 2009, The New England journal of medicine.
[236] S. Grundy. Pre-diabetes, metabolic syndrome, and cardiovascular risk. , 2012, Journal of the American College of Cardiology.
[237] J. McMurray,et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[238] R. Kitsis,et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. , 2003, The Journal of clinical investigation.
[239] V. Hasselblad,et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). , 2003, Journal of the American College of Cardiology.
[240] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[241] M. Quiñones,et al. Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[242] E. Olson,et al. Muscle : fundamental biology and mechanisms of disease , 2012 .
[243] Kevin Kit Parker,et al. Time-Warped Comparison of Gene Expression in Adaptive and Maladaptive Cardiac Hypertrophy , 2009, Circulation. Cardiovascular genetics.
[244] Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[245] S. Liggett. Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. , 2010, Heart failure clinics.
[246] Yuyang Sun,et al. Ca2+/Calmodulin-dependent Protein Kinase II-dependent Remodeling of Ca2+ Current in Pressure Overload Heart Failure* , 2008, Journal of Biological Chemistry.
[247] V. Vedantham,et al. Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors , 2010, Cell.
[248] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[249] J. Mant,et al. Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline , 2011, Annals of Internal Medicine.
[250] D. Kass,et al. Mechanisms of Enhanced &bgr;-Adrenergic Reserve From Cardiac Resynchronization Therapy , 2009, Circulation.
[251] Sachil Shah. Review: Heart failure with preserved ejection fraction in African Americans. , 2012, Ethnicity & disease.
[252] J. Schneider,et al. Targeting native adult heart progenitors with cardiogenic small molecules. , 2012, ACS chemical biology.
[253] B. Howard,et al. Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study , 2011, Journal of hypertension.
[254] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[255] H. McLeod,et al. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. , 2012, Journal of cardiac failure.
[256] G. Dwivedi,et al. Heart failure with preserved ejection fraction: current understanding and emerging concepts , 2013, Current opinion in cardiology.
[257] Arantxa González,et al. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.
[258] D. Kass,et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. , 1996, Circulation research.
[259] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[260] J. Pepper,et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.
[261] G. Dorn. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling , 2009, Nature Reviews Cardiology.
[262] R. Johnstone,et al. The genetic basis of family conflict resolution in mice , 2003, Nature.
[263] I. Anand,et al. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. , 2004, Journal of the American College of Cardiology.
[264] R. Sarangapani,et al. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi) , 2010, Journal of clinical pharmacology.
[265] Ziya Kaya,et al. Autoantibodies in heart failure and cardiac dysfunction. , 2012, Circulation research.
[266] A. Mihailidou,et al. Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction , 2012, Hypertension.
[267] S. Ball,et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. , 2009, Cardiovascular research.
[268] W. Koch,et al. Targeted &bgr;-Adrenergic Receptor Kinase (&bgr;ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .
[269] E. Olson,et al. Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy , 2006, Circulation.
[270] Joshua M Hare,et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.
[271] Shokei Kim,et al. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. , 1995, Hypertension.
[272] D. Bers,et al. Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.
[273] N. Dhalla,et al. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure , 2009, Heart Failure Reviews.
[274] N. Freemantle,et al. FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .
[275] Dariush Mozaffarian,et al. Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2010, Circulation.
[276] P. Galuppo,et al. Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction , 2001, Circulation.
[277] B. Dahlöf,et al. Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential , 2010, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[278] R. Canby,et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.
[279] C. Cooper,et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study , 2004, Heart.
[280] The obesity paradox: body mass index and outcomes in patients with heart failure , 2003 .
[281] D. Burke,et al. Age-associated activation of epigenetically repressed genes in the mouse. , 2003, Genetics.
[282] C. Seiler,et al. The impact of the coronary collateral circulation on mortality: a meta-analysis. , 2012, European heart journal.
[283] Mohit M. Jain,et al. Cardiac side population cells: moving toward the center stage in cardiac regeneration. , 2012, Circulation research.